ArticlePloS one2017
Radiosensitizing effect of diosmetin on radioresistant lung cancer cells via Akt signaling pathway.
Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Xiao-ai-ping injection adjunct with platinum-based chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis.BMC complementary medicine and therapies · 2020Pooled it
- Exploring the Multifaceted Potential of Natural Flavonoid Diosmetin in Human Diseases.Current pharmaceutical design · 2026Review
- Enhancement of doxorubicin efficacy by diosmetin through DNA damage accumulation and P-glycoprotein inhibition in breast cancer cells.Scientific reports · 2025Article
- Diosmetin Inhibits NETs Formation in Neutrophils Through Regulating Nrf2 Signaling.Thoracic cancer · 2025Article
- Recent Advances in Diosmetin: Pharmacological, Pharmacokinetic, and Toxicological Profile.Current topics in medicinal chemistry · 2025Review
- A Cross-Talk about Radioresistance in Lung Cancer-How to Improve Radiosensitivity According to Chinese Medicine and Medicaments That Commonly Occur in Pharmacies.International journal of molecular sciences · 2023Review
- Diosmetin Protects against Cardiac Hypertrophy via p62/Keap1/Nrf2 Signaling Pathway.Oxidative medicine and cellular longevity · 2022Article
- Use of cucurbitacins for lung cancer research and therapy.Cancer chemotherapy and pharmacology · 2021Review
- Biological Adaptations of Tumor Cells to Radiation Therapy.Frontiers in oncology · 2021Review
- Article
- Diosmetin enhances the sensitivity of radiotherapy by suppressing homologous recombination in endometrial cancer.Cell cycle (Georgetown, Tex.) · 2020Article
- Sulforaphane: Expected to Become a Novel Antitumor Compound.Oncology research · 2020Review
- Increased carcinoembryonic antigen expression on the surface of lung cancer cells using gold nanoparticles during radiotherapy.Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics (AIFB) · 2020Article
- Diosmetin alleviates hypoxia‑induced myocardial apoptosis by inducing autophagy through AMPK activation.Molecular medicine reports · 2020Article
- Preliminary study on radiosensitivity to carbon ions in human breast cancer.Journal of radiation research · 2020Article
- Review
- A novel topoisomerase I inhibitor DIA-001 induces DNA damage mediated cell cycle arrest and apoptosis in cancer cell.Annals of translational medicine · 2020Article
- Overexpression of GSDMC is a prognostic factor for predicting a poor outcome in lung adenocarcinoma.Molecular medicine reports · 2020Article
- Serum amyloid A1 as a biomarker for radiation dose estimation and lethality prediction in irradiated mouse.Annals of translational medicine · 2019Article
- The Roles of Plant-Derived Triptolide on Non-Small Cell Lung Cancer.Oncology research · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Radiotherapy is a powerful tool in the treatment of cancer that has the advantage of preserving normal tissues. However, tumor radioresistance currently remains a major impediment to effective RT. Thus, exploring effective radiation sensitizers is urgently needed. In this study, we have shown that diosmetin, the aglycone of the lavonoid glycoside from olive leaves, citrus fruits and some medicinal herbs, has a promising effect on radiotherapy sensitization. In our results, DIO could induce G1 phase arrest and thus enhance the radiosensitivity of radioresistant A549/IR lung cancer cells. Furthermore, DIO also restrains the IR-induced DNA damage repair by inhibiting the activated Akt signaling pathway. The combination of Akt inhibition (DIO, LY294002 or MK-2206) and radiation potently blocked A549/IR cancer cell proliferation. In summary, these observations suggest that the natural compound DIO could act as a potential drug for the treatment of radioresistant lung cancer cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.